Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.
A 21-year-old male experienced negative side effects from oral finasteride and is considering switching to topical finasteride or RU58841 after using oral minoxidil. He seeks advice on a standard hair loss routine, mentioning peptides, RU58841, and dermarolling.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
The user has been using pyrilutamide, topical finasteride, and 15% minoxidil for hair growth for almost 4 years. Despite mixed responses from others, the user reports seeing progress, especially with the addition of pyrilutamide, and plans to continue the regimen.
A user experienced androgenic alopecia starting at the vertex without frontal hairline recession and is seeking information on this pattern. Another user noted that vertex or diffuse hair loss is common among men.
A user experienced hair regrowth after 6 months on finasteride, which is earlier than the usual 12-18 months observed by their dermatologist. The dermatologist noted this as an exceptionally good response.
Fluridil was discussed as a hair loss treatment, with some users experiencing side effects like lethargy and chest tightness. Users also mentioned other treatments like RU58841 and finasteride, with mixed opinions on their effectiveness.
The user used minoxidil 5% and finasteride 0.1% for six months, along with a dermaroller and Nizoral shampoo, experiencing only dry scalp as a side effect. They are pleased with the results.
The user is experiencing breast tissue growth from taking dutasteride and minoxidil, and is considering reducing the dosage or stopping the medication. Suggestions include seeing an endocrinologist, using Raloxifene or Arimidex, and considering topical treatments or surgery if necessary.
The user has been using finasteride 1.2mg daily, topical minoxidil 1ml daily, tretinoin with topical minoxidil 1ml every other day, and a 1.5mm derma roller every two weeks for 8 months to treat hair loss. The user has posted progress pictures over time.
A 23-year-old male switched to a topical solution containing Fin 0.1% and Min 5% from a previous solution with Fin 1% and Min 5%, noticing increased hair shedding. He is concerned about losing around 50 hairs while using ketoconazole shampoo.
A 28-year-old male is experiencing hair loss, itching, soreness, and numbness on the scalp, with symptoms including dry, brittle hair and scalp irritation. Treatments tried include Nizoral, salt water, various oils, and antihistamines, with limited success; a chemist suggested a possible fungal infection, while a doctor suspected male pattern baldness.
The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.
The user has been using oral finasteride and minoxidil nightly, dutasteride twice a week, microneedling weekly, and pyripure nightly since April. They are seeking opinions on their hair regrowth progress, noting no slick bald areas but some miniaturized blonde hairs.
A user found relief from minoxidil-induced scalp itch by using a different product, as Nizoral dried out their scalp and worsened the condition. The conversation focuses on managing side effects of hair loss treatments.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
A user visited a dermatologist for hair loss concerns and was prescribed a hair lotion called "Lotion revolotion evdermia," which is meant for hair toning, hydration, and anti-aging, not regrowth. The user found the dermatologist's behavior and the prescription to be questionable.
The user experienced significant hair regrowth using a combination of minoxidil, finasteride (later switching to dutasteride), and tretinoin over two years. They noticed regrowth almost immediately, with no major initial shedding phase, and reported recession and diffuse hair loss patterns.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
A user reports persistent sexual side effects three months after stopping finasteride, despite a healthy lifestyle and supplements. They express concern over the lack of libido and infrequent erections.
A user's experience with Pyrilutamide, a topical treatment for hair loss that they used in combination with other treatments such as Minoxidil and Finasteride. The user experienced impressive results in a short amount of time.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
The user experienced significant hair regrowth over a year using topical finasteride (0.1%) and minoxidil (7%), along with Ketoconazole shampoo, and recently switched to dutasteride and plans to add oral minoxidil. They managed side effects like oily skin and itchiness with a corticosteroid and chose topical treatments initially to limit systemic exposure.
The user experienced hair shedding and follicle shrinkage when using retinoic acid, despite trying different concentrations and frequencies. The hair loss persisted for six months but regrew after stopping the treatment.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.
The user had been using Minoxidil and Dutasteride with micro-needling but experienced hair loss after switching Minoxidil brands. Their doctor prescribed oral Minoxidil and Tretinoin, but the pharmacist suggested isotretinoin might be a more cost-effective alternative.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users share experiences and support, mentioning that many people face hair thinning.
The user is using topical minoxidil and finasteride with good results and is considering adding stemoxydine 5% to their regimen. Another user suggests trying it if financially feasible, as results can vary.
A user is considering combining oral and topical dutasteride to lower scalp DHT more effectively and is seeking advice on this approach. They are thinking about doing a patch test on their mid scalp.